For patients with diabetes, hemoglobin A1c(HbA1c)treatment goals are based primarily on evaluating the outcomes and responses of the average patient. However, the American Diabetes Association and the American Association of Clinical Endocrinologists now recommend individualizing treatment regimens and HbA1c goals by including patient-centered and sociodemographic characteristics that might impact heterogeneity of treatment effect (HTE) for diabetes treatment.
